LOCALLY ADVANCED BREAST CANCER
Clinical trials for LOCALLY ADVANCED BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new LOCALLY ADVANCED BREAST CANCER trials appear
Sign up with your email to follow new studies for LOCALLY ADVANCED BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for breast cancer patients: extra targeted drug may clear remaining tumors
Disease control Not yet recruitingThis study tests whether adding 4 cycles of the targeted drug trastuzumab rezetecan (T-DXh) can eliminate residual cancer in HER2-positive breast cancer patients who still have disease after standard chemotherapy. About 59 adults will receive the drug before surgery. The main goa…
Matched conditions: LOCALLY ADVANCED BREAST CANCER
Phase: PHASE4 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New drug duo aims to wipe out breast cancer before surgery
Disease control Not yet recruitingThis study tests a new drug combination (SHR-A1811 plus pertuzumab) given before surgery to women with early or locally advanced HR-positive, HER2-positive breast cancer. The goal is to see if this treatment can eliminate all cancer cells in the breast and lymph nodes by the time…
Matched conditions: LOCALLY ADVANCED BREAST CANCER
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Mind over tumor: short therapy may improve chemo response in breast cancer
Symptom relief Not yet recruitingThis study tests whether a short psychological therapy called Brief Acceptance and Commitment Therapy (Brief-ACT) can help chemotherapy work better in women with locally advanced breast cancer. Fifty-four participants will either receive standard chemotherapy alone or with Brief-…
Matched conditions: LOCALLY ADVANCED BREAST CANCER
Phase: NA • Sponsor: Universitas Airlangga • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC